Gastric Cancer

[vc_row][vc_column][vc_column_text]

GASTRIC CANCER

Gastric cancer is a disease in which cancer cells form in the stomach lining. The stomach is present on the upper abdomen and helps to digest food.

Almost all gastric cancers are adenocarcinomas (cancers that begin in cells that make and release mucus and other types of fluids). Other types of gastric cancer are gastrointestinal carcinoid tumors, lymphomas and gastrointestinal stromal tumors. These type of cancer doesn’t cause any symptoms and it is very difficult to detect, treatment of cancer can be done by chemotherapy, radiation therapy or by surgery.

Stomach cancer occurs when normally healthy cells within the upper digestive system become cancerous and grow out of control and form a tumor. This process happens slowly so that stomach cancer tends to develop over many years.

Stomach cancer is more common among older adults (usually those 50 years and older), men, smokers, those with a family history of the disease, individuals who are of Asian (especially Korean or Japanese), South American, or Belarusian descent

Facts of Cyramza 100mg Vial ?

  • Medicine Name: Cyramza
  • Generic Name: Ramucirumab
  • Approval Date: 2014
  • Company Name: Eli Lilly and Company.
  • Available as (Form & Strength):
    100mg/10mL(10mg per mL) solution, single-dosevial
    500mg/50mL(10mg per mL) solution, single-dosevial

INDICATIONS AND USAGE

Gastric Cancer
CYRAMZA ® as a single agent , or in combination with paclitax el, is indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine-orplatinum-containingchemotherapy.

Non-Small Cell Lung Cancer

CYRAMZA, in combination with docetaxel, is indicated for the treatment of patients with metastatic non -small cell lung cancer (NSCLC)with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA

Colorectal Cancer

CYRAMZA,in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil),is indicated for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and afluoropyrimidine.

How supplied/storage and handling ?

Store vials in a refrigerator at 2°C to 8°C (36°F to 46°F) until time of use. Keep the vial in the outer carton in order to protect from light. DO NOT FREEZE OR SHAKE the vial.

For product diluted in 0.9% sodium chloride, the chemical and physical stability have been demonstrated for up to 24 hours at 2°C to 8°C (36°F[/vc_column_text][/vc_column][/vc_row]